ABN AMRO Bank N.V. Purchases Shares of 191,290 Gilead Sciences, Inc. $GILD

Key Points

• ABN AMRO Bank initiated a sizable Gilead Sciences position, purchasing 191,290 shares worth approximately $24.2 million in the second quarter. Institutional investors collectively own 83.67% of Gilead.
• Gilead reported 10.6% year-over-year revenue growth to $7.8 billion in its latest quarter, driven by strength in its HIV franchise and PrEP sales. The company also declared a quarterly dividend of $0.82 per share, representing a 2.4% yield.
• Wall Street maintains a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $158.04 versus the stock’s reported $138.36 price. Growth opportunities include oncology and AI-supported drug development, although an analyst lowered the FY2026 EPS forecast and insiders have sold shares.

ABN AMRO Bank N.V. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 191,290 shares of the biopharmaceutical company's stock, valued at approximately $24,159,000.

A number of other hedge funds have also recently made changes to their positions in GILD. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences in the fourth quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC grew its stake in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new position in Gilead Sciences during the 4th quarter valued at about $26,000. Wealth Preservation Advisors LLC raised its position in Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Wilkerson Advisory Group LLC raised its position in Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 78 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Appeals court ruling protects Gilead’s distribution channels. A U.S. appeals court upheld an injunction preventing alternative funding programs and related businesses from importing Gilead medications overseas. The decision could reduce the size of the alternative funding industry and help protect Gilead’s pricing, sales channels and patient-assistance economics. Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
• Positive Sentiment: Q2 growth highlighted continued commercial momentum. Gilead’s HIV franchise led year-over-year sales growth, with Biktarvy and PrEP performing particularly well. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy, Livdelzi and progress in oncology and liver disease added to the growth outlook. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI collaboration strengthens the oncology pipeline. Gilead partnered with Nucleai to use AI-powered tissue analytics in its antibody-drug-conjugate programs. The technology is intended to accelerate biomarker discovery and improve precision-oncology development. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Merck partnership offers longer-term growth potential. Recent clinical and regulatory progress involving Gilead and Merck’s collaboration reinforces the possibility that the partnership could produce meaningful future growth in areas such as oncology and infectious disease. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Neutral Sentiment: Analysts and investors continue to debate whether Gilead remains attractively valued after its strong multiyear performance. High call-option activity signals bullish positioning but does not guarantee sustained gains.
• Negative Sentiment: An analyst reduced the FY2026 EPS forecast, potentially reflecting concerns about earnings normalization, expenses or pipeline investment. The revision may limit near-term upside despite Gilead’s solid revenue trends. FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst

Gilead Sciences Trading Up 0.2%

NASDAQ GILD opened at $138.36 on Friday. The firm has a market capitalization of $171.56 billion, a PE ratio of -51.82 and a beta of 0.32. The stock's 50 day moving average is $130.11 and its 200 day moving average is $136.45. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the prior year, the firm earned $2.01 EPS. The company's revenue was up 10.6% compared to the same quarter last year. Research analysts forecast that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently -122.85%.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent analyst reports. Royal Bank Of Canada lifted their price objective on Gilead Sciences from $120.00 to $123.00 and gave the stock a "sector perform" rating in a research report on Wednesday, August 5th. HSBC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $133.00 to $155.00 in a report on Monday, July 6th. Needham & Company LLC reissued a "buy" rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Cantor Fitzgerald restated an "overweight" rating and issued a $155.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 5th. Finally, Maxim Group raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 target price on the stock in a research note on Wednesday, May 20th. Twenty-four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $158.04.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 15,000 shares of the firm's stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the transaction, the chief executive officer owned 617,567 shares of the company's stock, valued at $81,185,357.82. This trade represents a 2.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider owned 124,234 shares of the company's stock, valued at $15,395,077.28. The trade was a 2.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 51,000 shares of company stock worth $6,568,860. Insiders own 0.30% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source